Instrucciones de búsqueda:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Navegar por los elementos (107 total)
-
Autor: PRINCIPLE Trial Collaborative Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-03-04
Descripción: Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties, has been used to treat COVID-19, but evidence from community randomised trials is lacking. We aimed to assess the effectiveness of azithromycin to treat suspected… -
Autor: The RECOVERY Collaborative Group.
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-02-25
Descripción: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. -
Autor: The REMAP-CAP Investigators
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-02-25
Descripción: The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. -
Autor: the PlasmAr Study Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-02-18
Descripción: Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled… -
Autor: the Fundación INFANT–COVID-19 Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-02-18
Descripción: Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier… -
Autor: The RECOVERY Collaborative Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-02-02
Descripción: Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.A response to this article was… -
Autor: Huang, Edmund, and Stanley C. Jordan.
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2020-12-10
Descripción: Nearly 10 months after the identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the virus responsible for coronavirus disease 2019 (Covid-19), therapeutic options remain limited. -
Autor: WHO Solidarity Trial Consortium
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2020-12-02
Descripción: World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a — in patients hospitalized with coronavirus disease 2019 (Covid-19). -
Autor: Cavalcanti, Alexandre B., Fernando G. Zampieri, Regis G. Rosa, Luciano C. P. Azevedo, Viviane C. Veiga, Alvaro Avezum, Lucas P. Damiani, Aline Marcadenti, Letícia Kawano-Dourado, Thiago Lisboa, Debora L. M. Junqueira, Pedro G. M. de Barros e Silva,…
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2020-11-19
Descripción: Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited. -
Autor: The RECOVERY Collaborative Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2020-11-19
Descripción: Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials.